Use of omalizumab to improve desensitization safety in allergen immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 133, Issue 3, 2014, Pages

  Larenas Linnemann, Désirée ^a   Wahn, Ulrich ^b   Kopp, Matthias ^c  

^a LIVER RESEARCH UNIT   (Mexico)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALLERGEN; EOSINOPHIL CATIONIC PROTEIN; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; LEUKOTRIENE; OMALIZUMAB; RAGWEED ANTIGEN; TRYPTASE; VENOM;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; BIRCH; CAT; DAIRY PRODUCT; DERMATOPHAGOIDES; DESENSITIZATION; DISEASE EXACERBATION; DRUG SAFETY; GRASS POLLEN; HEADACHE; HIGH RISK PATIENT; HOUSE DUST ALLERGY; HUMAN; HYMENOPTERA; KAPOSI VARICELLIFORM ERUPTION; LUNG FUNCTION; MAINTENANCE THERAPY; MILK ALLERGY; MODERATE PERSISTENT ASTHMA; OFF LABEL DRUG USE; POLLEN ALLERGY; PREMEDICATION; PRIORITY JOURNAL; RAGWEED; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBCUTANEOUS VENOM IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; WINTER;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS;

EID: 84896856584     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.12.1089     Document Type: Review

References (19)

1. J. Kuehr, J. Brauburger, S. Zielen, U. Schauer, W. Kamin, and A. Von Berg et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis J Allergy Clin Immunol 109 2002 274 280
2. C. Rolinck-Werninghaus, E. Hamelmann, T. Keil, M. Kulig, K. Koetz, and B. Gerstner et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children Allergy 59 2004 973 979
3. M.V. Kopp, J. Brauburger, F. Riedinger, D. Beischer, G. Ihorst, and W. Kamin et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis J Allergy Clin Immunol 110 2002 728 735
4. C. Bez, R. Schubert, M. Kopp, Y. Ersfeld, M. Rosewich, and J. Kuehr et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis Clin Exp Allergy 34 2004 1079 1085
5. M.V. Kopp, E. Mayatepek, E. Engels, J. Brauburger, F. Riedinger, and G. Ihorst et al. Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (omalizumab) Pediatr Allergy Immunol 14 2003 401 404
6. M.V. Kopp, S. Stenglein, W. Kamin, F. Friedrichs, A. von Berg, and S. Zielen et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects Pediatr Allergy Immunol 18 2007 523 527
7. T.B. Casale, W.W. Busse, J.N. Kline, Z.K. Ballas, M.H. Moss, and R.G. Townley et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis J Allergy Clin Immunol 117 2006 134 140
8. S. Klunker, L.R. Saggar, V. Seyfert-Margolis, A.L. Asare, T.B. Casale, and S.R. Durham et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding J Allergy Clin Immunol 120 2007 688 695
9. M. Massanari, H. Nelson, T. Casale, W. Busse, F. Kianifard, and G.P. Geba et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma J Allergy Clin Immunol 125 2010 383 389
10. M.V. Kopp, E. Hamelmann, S. Zielen, W. Kamin, K.C. Bergmann, and C. Sieder et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma Clin Exp Allergy 39 2009 271 279
11. M.V. Kopp, E. Hamelmann, M. Bendiks, S. Zielen, W. Kamin, and K.C. Bergmann et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy Pediatr Allergy Immunol 24 2013 427 433
12. C. Galera, N. Soohun, N. Zankar, S. Caimmi, C. Gallen, and P. Demoly Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab J Invest Allergol Clin Immunol 19 2009 225 229
13. V. Soriano Gomis, P. Gonzalez Delgado, and E. Niveiro Hernandez Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy J Invest Allergol Clin Immunol 18 2008 225 226
14. A. Nopp, S.G. Johansson, J. Ankerst, M. Palmqvist, and H. Oman CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment Allergy 62 2007 1175 1181
15. A. Nopp, S.G. Johansson, J. Adedoyin, J. Ankerst, M. Palmqvist, and H. Oman After 6 years with Xolair; a 3-year withdrawal follow-up Allergy 65 2010 56 60
16. P.J. Lowe, and D. Renard Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE Br J Clin Pharmacol 72 2011 306 320
17. W. Kamin, M.V. Kopp, F. Erdnuess, U. Schauer, S. Zielen, and U. Wahn Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously Pediatr Allergy Immunol 21 2010 e160 e165
18. W. Busse, R. Buhl, C. Fernandez Vidaurre, M. Blogg, J. Zhu, and M.D. Eisner et al. Omalizumab and the risk of malignancy: results from a pooled analysis J Allergy Clin Immunol 129 2012 983 989.e6
19. K.C. Nadeau, L.C. Schneider, L. Hoyte, I. Borras, and D.T. Umetsu Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy J Allergy Clin Immunol 127 2011 1622 1624